Alps Advisors Inc Larimar Therapeutics, Inc. Transaction History
Alps Advisors Inc
- $17.2 Billion
- Q1 2025
A detailed history of Alps Advisors Inc transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 47,460 shares of LRMR stock, worth $96,818. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47,460
Previous 51,590
8.01%
Holding current value
$96,818
Previous $197,000
48.22%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding LRMR
# of Institutions
109Shares Held
64.5MCall Options Held
93.5KPut Options Held
68K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$43.3 Million1.16% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$12.3 Million0.27% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$11.4 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.78MShares$9.75 Million5.31% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$6.97 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $88.3M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...